Cerebral Vasoconstriction Triggered By Sympathomimetic Drugs During Intra-atrerial Chemotherapy

• Published in: Pediatric neurology Vol. 48; no. 2; pp. 139 - 142
• Main Authors: Abruzzo, Todd, MD, Patino, Mario, MD, Leach, James, MD, PhD, Rahme, Ralph, MD, Geller, James, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2013
• Subjects: Angiography; Antineoplastic Agents, Alkylating - therapeutic use; Arteries; Cerebral infarction; Chemotherapy; Children; Drugs; Eye; Female; Headache; Hemorrhage; Humans; Infant; Intravenous administration; Magnetic resonance imaging; Melphalan; Melphalan - therapeutic use; Neuroimaging; Neurology; Pediatrics; Perfusion; Phenylephrine - adverse effects; Phenylephrine - therapeutic use; Retinal Neoplasms - drug therapy; retinoblastoma; Retinoblastoma - drug therapy; Stroke; Sympathomimetics; Sympathomimetics - adverse effects; Sympathomimetics - therapeutic use; Vasoactive agents; Vasoconstriction; Vasospasm, Intracranial - chemically induced
• ISSN: 0887-8994; 1873-5150
• DOI: 10.1016/j.pediatrneurol.2012.10.005

Abstract Reversible cerebral vasoconstriction syndrome is a rare cause of headache and stroke in the pediatric population. Reversible vasoconstriction is reported in a 19-month-old girl with retinoblastoma who underwent selective ophthalmic artery infusion chemotherapy with melphalan. Procedure-related cerebral vasoconstriction was specifically triggered during coadministration of adjunctive medications, which included mydriatic eye drops containing phenylephrine, intranasal oxymetazoline, nebulized albuterol, intravenous hydrocortisone, and intravenous diphenhydramine. The course of cerebral vasospasm, which began with a severe hypertensive surge and resolved spontaneously within hours of blood pressure normalization, was documented by angiography in real time. Subsequent brain magnetic resonance imaging showed no evidence of perfusion abnormality, cerebral infarction, or cerebral hemorrhage, and the patient was discharged home without any neurologic sequelae. In this report, we highlight the potential risk of reversible cerebral vasoconstriction in children administered vasoactive drugs and discuss its relevance during treatment of retinoblastoma by intraarterial chemotherapy.